- In September 2019, Xeltis, a Swiss startup, has completed a USD 11.69 million Series D funding round to fund its valve and vascular research services. Established private and institutional investors, as well as all previous venture capitalists, contributed to the funding. Cardiovascular disease is the world's biggest cause of death. Through a therapy procedure known as ETR, Xeltis devices are designed to facilitate normal regeneration of the patient's blood vessels and hence cardiac function (Endogenous Tissue Restoration).
